comscoreGenetic Testing

Genetic Testing

49 Research news
 
 
Article
Society Develops New Guidelines on Prophylactic Ovary Removal

New guidelines on protectively removing both ovaries and the fallopian tubes address the role this surgery can play in reducing the risk of both ovarian and breast cancer.

 
Article
Women With Abnormal BRCA Gene Have Higher Risk of New Cancer in Opposite Breast

Research shows that women with an abnormal BRCA1 or BRCA2 gene who've been diagnosed with breast cancer have a higher risk of being diagnosed with a new, different cancer in the opposite breast compared to women without an abnormal BRCA1 or BRCA2 gene.

 
Article
Unclear Explanation of Genetic Testing Results Seems to Affect Treatment Decisions

A study suggests that genetic test results are not being clearly communicated to women and may be causing them to opt for breast cancer treatment that is more aggressive than they need.

 
Article
Pregnancy After Breast Cancer Seems Safe for Women With BRCA Mutation

Women with a BRCA1 or BRCA2 mutation who become pregnant after being treated for breast cancer don't have a higher risk of recurrence and their babies are healthy.

 
Article
Risk of Breast, Ovarian Cancer May Vary Depending on Type and Location of BRCA Mutation

A study suggests that a woman's risk of breast and ovarian cancer may vary depending on the type of mutation a woman has and where the mutation is located on the BRCA1 or BRCA2 gene.

 
Article
Study Suggests Breast Cancer Screening Options for Women With ATM, CHEK2, and PALB2 Mutations

Women with ATM, CHEK2, or PALB2 mutations may benefit from starting annual breast cancer screening with MRI between the ages and 30 to 35 and an annual MRI and mammogram starting at age 40.

 
Article
FDA Approves Talzenna to Treat Metastatic Breast Cancer in Women With BRCA Mutations

The FDA has approved Talzenna (chemical name: talazoparib) to treat locally advanced or metastatic HER2-negative breast cancer in women with an inherited BRCA1 or BRCA2 mutation.

 
Article
Study Estimates Breast Cancer Risk by Age for Women With BRCA Mutations

A study estimates the risk of breast and ovarian cancer by age, taking into account family history and mutation location for women with a BRCA mutation.

Jun 30, 2017 | Genetic Testing and Risk Factors
 
Article
Women Who Don't Have Abnormal Breast Cancer Gene Have Average Risk, Even if Relatives Test Positive

Research shows that a woman who tests negative for an abnormal BRCA1 or BRCA2 gene but has a family history of breast cancer and a first-degree relative who's tested positive for BRCA1 or BRCA2 has the same risk of breast cancer as a woman with a family history of breast cancer but no relatives with an abnormal gene.

Nov 1, 2011 | Genetic Testing and Diagnosis
 
Article
Experimental Targeted Therapy May Help Treat People With Advanced-Stage Cancer Due to Abnormal BRCA Gene

A study found that more than 25% of people with an abnormal BRCA1 or BRCA2 gene being treated for advanced-stage breast, ovarian, pancreatic, or prostate cancer got some benefit from olaparib, an experimental targeted therapy medicine.

 
Article
Abnormal BRCA1 or BRCA2 Gene Increases Risk, Amount Varies Widely

A new study shows that the increase in risk associated with an abnormal BRCA1 or BRCA2 gene can vary widely among people who have an abnormal gene.

 
Article
Some Parents Who've Been Tested Support Abnormal Breast Cancer Gene Testing for Kids

About a third of people who were tested for abnormal breast cancer genes (BRCA1 or BRCA2), supported the same testing for their children.

 
Article
New Type of Targeted Therapy May Help Treat Triple-Negative Disease

Experimental targeted therapy medicines -- called PARP inhibitors -- may make chemotherapy work better against aggressive forms of breast cancer and also may be able to treat breast cancer alone, without chemotherapy.

 
Article
Abnormal BRCA1 Gene Linked to Worse Outcomes Than Abnormal BRCA2 Gene

A study suggests women with an abnormal BRCA1 gene have worse breast cancer survival and recurrence rates than women with an abnormal BRCA2 gene or women who don't have either abnormal gene.

 
Article
Genetic Test Results Can Offer Peace of Mind

Women at high risk for breast cancer who had genetic testing benefited psychologically from knowing the results of the test.

 
Article
Parents Often Tell Kids About Abnormal Genes Before Interventions Needed

New research suggests that parents should wait until their children reach early adulthood before talking to them about abnormal genetic test results.

 
Article
BRCA1 Mutation Linked to Fewer Eggs in Ovaries

A study found that women with a BRCA1 mutation had levels of a hormone that indicates how many eggs are left in the ovaries that were 25% lower than women who didn't have the mutation.

 
Article
Women With Abnormal BRCA1 Gene Benefit From Having Ovaries and Fallopian Tubes Removed; Quality of Life Affected

A study suggests that women with an abnormal BRCA1 gene diagnosed with breast cancer are more likely to survive if they have their ovaries and fallopian tubes removed. Still, another study suggests that women who have the surgery have lower quality of life.

 
Article
Women With BRCA1 Gene Mutation Have Fewer Eggs in Ovaries

Women with a mutation in the BRCA1 gene likely have fewer eggs in their ovaries than the average woman, which may shorten their window of opportunity to have children.

 
Article
Study Estimates Ashkenazi Jewish Women's Risk of Having Mutations Other Than BRCA1 and BRCA2

Research suggests that comprehensive genetic testing for Ashkenazi Jewish women, rather than only testing for the three BRCA1 or BRCA2 founder mutations, would help prevent breast cancer in this high-risk population.

 
Article
Women With Breast Cancer Gene Mutation Have Same or Better Survival as Women Without Mutation

Women with a genetic mutation linked to a higher cancer risk who are diagnosed with breast cancer or ovarian cancer and receive chemotherapy treatment have the same or better survival rates as women who don’t have a genetic mutation linked to higher risk.

 
Article
Diagnosed Women With Abnormal Breast Cancer Gene Have Higher Risk of New Cancer in Opposite Breast

Research suggests that women with an abnormal BRCA1 or BRCA2 gene who have been diagnosed with breast cancer are 4 times more likely to be diagnosed with a new cancer in the opposite breast compared to women without an abnormal breast cancer gene diagnosed with breast cancer.

 
Article
Lynparza Offers Benefits for Early-Stage HER2-Negative Breast Cancer With BRCA1/2 Mutation

Adding Lynparza to standard treatment for early-stage HER2-negative breast cancer with a high risk of recurrence in people with a BRCA1 or BRCA2 mutation improved disease-free survival.

 
Article
Veliparib Maintenance After Chemo Slightly Improves Outcomes for Metastatic HER2-Negative Breast Cancer With BRCA Mutations

People diagnosed with metastatic HER2-negative breast cancer with a BRCA1 or BRCA2 mutation treated with experimental veliparib and chemotherapy lived about 2 months longer without the cancer growing if they continued on veliparib after stopping chemotherapy.

Showing 24 of 49